pharmaceutical-investing Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program
pharmaceutical-investing AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib in Adults and Adolescents With Vitiligo
pharmaceutical-investing AbbVie Launches Love in Mind to Spotlight the Emotional Impact of Migraine on Romantic Relationships
pharmaceutical-investing Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine
pharmaceutical-investing AbbVie Announces Topline Results for Epcoritamab from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
pharmaceutical-investing AbbVie Announces Topline Results for Epcoritamab from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
pharmaceutical-investing AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans
pharmaceutical-investing AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors
pharmaceutical-investing AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States
pharmaceutical-investing West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie
pharmaceutical-investing MAVIRET® receives Health Canada Approval for the Treatment of Acute Hepatitis C Virus
pharmaceutical-investing AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
